Mark Silverberg, MD
Pediatric Ophthalmology and Strabismus Specialist · Santa Barbara, CANPI 1366544488
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,690 of the $5,255 with a category attached, or 70.2%. 23 manufacturers reported payments, led by Kala Pharmaceuticals, Inc. at 28.5% of the total. Reporting peaked in 2021 at $2,004 and has fallen 68.5% since, to $632 in 2025.
Across 77 payments — averaging $68.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kala Pharmaceuticals, Inc.$2K
- Amgen$506
- Regeneron Healthcare Solutions, Inc.$461
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$409
- AbbVie$278
- Bausch & Lomb Americas Inc.$235
- plus $2K from 17 others
Across 6 payments — averaging $3158.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$12K
- Novartis$7K
What the payments were for
- Consulting fees$1,50029%
- Food & beverage$3,69070%
- Education$90%
- Gifts$190%
- Entertainment$361%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kala Pharmaceuticals, Inc. | 1 | $1,500 |
| Amgen(2 entities) | 9 | $506 |
| Regeneron Healthcare Solutions, Inc. | 4 | $461 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 31 | $409 |
| AbbVie(2 entities) | 5 | $278 |
| Bausch & Lomb Americas Inc. | 3 | $235 |
| NEW World Medical,inc. | 2 | $231 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $222 |
| Johnson & Johnson | 1 | $212 |
| Glaukos Corporation | 2 | $199 |
| Osmotica Pharmaceutical Corp. | 1 | $147 |
| Tarsus Pharmaceuticals, Inc. | 2 | $145 |
| Alcon | 1 | $141 |
| Biogen | 1 | $130 |
| Harrow Eye, LLC | 1 | $125 |
| Sun Pharmaceutical Industries Inc. | 1 | $121 |
| Dompe US, Inc. | 2 | $68 |
| Optos, Inc. | 1 | $36 |
| Oyster Point Pharma, Inc. | 1 | $24 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Novartis | 1 | $18 |
| Leadiant Biosciences, Inc. | 1 | $18 |
| Travere Therapeutics, Inc. | 3 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYSUVIS$1,500
- EYLEA$335
- TEPEZZA$247
- SPRAVATO$212
- Kahook Dual Blade$171
- Streamline Surgical System$171
- Ahmed Glaucoma Valve$171
- AcrySof IQ PanOptix$141
- iStent inject Trabecular Micro-Bypass Stent System$132
- XDEMVY$128
- EYLEA HD$126
- VEVYE$125
- VYZULTA$125
- CEQUA$121
- LOTEMAX SM$111
How this compares
$5,255 in reported general payments places this provider in the 85th percentile of 28 pediatric ophthalmology and strabismus specialist providers in California.
See all pediatric ophthalmology and strabismus specialist providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 25 | $17,796 |
| RestasisCyclosporine | 14 | $13,591 |
| Cyclosporine | 29 | $7,061 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 44 | $1,535 |
| Latanoprost | 22 | $178 |
| Timolol Maleate | 13 | $142 |
| ErythromycinErythromycin Base | 14 | $135 |
| Brimonidine Tartrate | 12 | $45 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra | $235 | $17,79625 claims |
| AbbVieRestasis | $278 | $13,59114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 28 pediatric ophthalmology and strabismus specialist providers in California.
Other pediatric ophthalmology and strabismus specialist in Santa Barbara
- Scott LambertPalo Alto$20K
- Donny SuhIrvine$14K
- Leila KhazaeniLoma Linda$9K
- Euna KooPalo Alto$6K
- Jennifer DunbarSan Bernardino$5K
- Shira RobbinsSan Diego$5K
- Mona FayadLos Angeles$3K
- Douglas FredrickDaly City$2K
- Ann ShueStanford$1K
- Sheryl HandlerEncino$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.